Table 1 Clinicopathologic features of the 70 patients classified according to radioiodine (RAI) avidity/refractoriness and disease status
From: The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
Clinicopathologic features | RAI+/D+ (23) | RAI−/D+ (32) | RAI+/D- (15) | P |
|---|---|---|---|---|
Age at diagnosis (years), median ± SD | 44 ± 20.5 | 47 ± 18.7 | 44 ± 16.6 | 0.81 |
Female gender, n (%) | 16 (70) | 21 (66) | 10 (67) | 0.95 |
Tumor diagnosis, n (%) | ||||
 Incidental | 4 (17) | 5 (16) | 1 (7) | 0.62 |
 Pre-surgical | 19 (83) | 27 (84) | 14 (93) |  |
Tumor size (mm), median (IQR) | 2.3 (0.9–0.6) | 2.2 (0.7–4.2) | 2.4 (1.2–5) | 0.27 |
Histological variant, n (%) | ||||
 CPTC | 19 (83) | 29 (90) | 10 (67) | 0.001 |
 FVPTC | 0 | 3 (10) | 5 (33) |  |
 SCL/COL/TALL/PDTC | 2/0/1/1 (9/0/4/4) | 0/0/0/0 | 0/0/0/0 |  |
Extrathyroidal Invasion, n (%) | ||||
 Yes | 18 (78) | 18 (56) | 10 (67) | 0.23 |
 No | 5 (22) | 14 (44) | 5 (33) |  |
Multifocality, n (%) | ||||
 Yes | 16 (70) | 17 (53) | 12 (80) | 0.16 |
 No | 7 (30) | 15 (47) | 3 (20) |  |
TNM, n (%) | ||||
  T1 | 3 (13) | 8 (25) | 2 (13) | 0.28 |
  T2-T3-T4 | 20 (87) | 24 (75) | 13 (87) |  |
  N0 | 0 (0) | 6 (19) | 0 (0) | 0.24 |
  N1 | 23 (100) | 26 (81) | 15 (100) |  |
  M0 | 18 (78) | 25 (78) | 15 (100) | 0.13 |
  M1 | 5 (22) | 7 (22) | 0 |  |
AJCC stage, n (%) | ||||
 I | 13 (57) | 15 (47) | 9 (60) | 0.64 |
 II-III-IV | 10 (43) | 17 (53) | 6 (40) |  |
ATA risk stratification, n (%) | ||||
 Low | 0 (0) | 0 (0) | 0 (0) | 0.61 |
 Intermediate/High | 22/1 (96/4) | 30/2 (94/6) | 15/0 (100/0) |  |
Cumulative dose of RAI (mCi) median ± SD | 85 ± 47.8 | 76 ± 37.1 | 75 ± 33.4 | 0.21 |